Traws Pharma, Inc. announced on March 24, 2025, that its antiviral bird flu program, tivoxavir marboxil (TXM), demonstrated positive data in non-human primates. A single dose of TXM significantly reduced lung viremia and prevented weight loss, which are critical measures of antiviral activity in preclinical bird flu models.
These results build upon earlier positive findings of mortality benefit for TXM in ferret and murine models. The consistent efficacy across multiple accepted animal models strengthens the case for TXM's potential as a treatment for H5N1 bird flu.
The company is preparing FDA briefing documents for discussions regarding a potential accelerated path to approval for tivoxavir marboxil. This data will be further detailed at an upcoming Investor Event on March 31, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.